Journal of cancer research and therapeutics,
10/2015, Letnik:
11, Številka:
4
Report
Von Hippel-Lindau disease (VHL) is a major heritable renal cell cancer (RCC) syndrome. 24-45% of VHL patients have a cumulative risk to develop RCC. The management of VHL has changed significantly as clinicians have learned how to best balance the risk of cancer dissemination while minimizing renal morbidity. Despite the improving management of this disease, there are no evidence-based guidelines of the treatment of localized and advanced RCC in VHL. Here, we describe a 39-year-old patient with VHL disease who developed metastatic RCC and received sunitinib with complete remission.
Bibliografsko gradivo je bilo uspešno dodano na polico.
Dodajanje bibliografskega gradiva na polico ni uspelo.
Gradivo je že na polici.
Trajna povezava
URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto
Faktor vpliva
Izdaja
Kategorija
Razvrstitev
JCR
SNIP
JCR
SNIP
JCR
SNIP
JCR
SNIP
Izberite knjižnično izkaznico:
Baze podatkov,
v katerih je revija indeksirana
Ime baze podatkov
Področje
Leto
Povezave do osebnih bibliografij avtorjev
Povezave do podatkov o raziskovalcih v sistemu SICRIS
PDF